This Internet symposium will review and discuss the key studies on chronic hepatitis C management and treatment presented at EASL. The symposium will feature four well-known and recognized thought leaders in the HCV field, with three serving as presenting faculty/discussants and one as program moderator.
This activity has been designed to meet the educational needs of physicians involved in the care of patients with chronic hepatitis C infection. This program is certified for CME credit for US physicians by the Postgraduate Institute for Medicine.
This activity is intended for physicians, physician assistants, advanced practice nurses, and other health care professionals involved in the treatment and management of patients with HCV infection.
After completing this activity, participants should be able to:
Implement appropriate monitoring and testing;
Explain and use, in a clinical setting, the key new studies on chronic hepatitis C management and treatment presented at the 47th EASL;
Apply treatment paradigms for chronic hepatitis C;
Discuss with patients the studies and data on newer therapies for chronic hepatitis C presented at the 47th EASL;
Apply information on newer therapies in therapeutic discussions.
Release Date: May 1, 2012
Expiration Date: May 1, 2013
Estimated time to complete the EASL 2012 Web Symposium: 1 hour, 45 minutes
Media: Internet
Mark Sulkowski, MD
Associate Professor of Medicine and Medical Director,
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland
Nezam H. Afdhal, MD
Associate Professor of Medicine,
Harvard School of Medicine
Chief of Hepatology, Director of Liver Center,
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Fred Poordad, MD
Chief, Hepatology
Cedars-Sinai Medical Center
Associate Professor of Medicine,
David Geffen School of Medicine at UCLA
Los Angeles, California
K. Rajender Reddy, MD
Professor of Medicine,
Director of Hepatology,
Medical Director of Liver Transplantation
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Postgraduate Institute for Medicine and ViralEd, Inc.. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)TM.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Postgraduate Institute for Medicine assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Postgraduate Institute for Medicine for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Postgraduate Institute for Medicine is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Dr. Mark Sulkowski:
Contracted Research: Merck; Roche; Vertex; Gilead; BIPI; Janssen; BMS; Abbott
Consulting Fees: Merck; Roche; Vertex; Gilead; BIPI; Janssen; BMS; Abbott
Dr. Nazim Afdhal:
Contracted Research: Schering Plough/Merck; Novartis; GSK; Echosens; Vertex; Gilead; Quest
Consulting Fees: Gilead; Echosens; Biogen; GSK; Vertex; Novartis; Idera Pharmaceuticals; Boehringer Ingelheim; HGS; Biolex; Fibrogen; Ligand; Schering Plough/Merck
Dr. K. Rajender Reddy:
Contracted Research: BMS; Tibotec; Gilead; Merck; Anadys; Pharmasset
Advisory Boards: Genentech; Merck; Tibotec; Salix; Vertex
Dr. Fred Poordad:
Contracted Research: Salix; Vertex; Schering-Plough; Roche; HGS; Novartis; Valeant; Idenix; Gilead; Abbott; BMS; Zymogenetics; Onyx; Merck
Advisory Boards: Salix; Merck; Genentech; Gilead; Abbott; Idenix; Tibotec
Fees for Non-CME/CE Services: Gilead; Genentech; Salix
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
The following PIM staff serve as clinical content reviewers and/or participate in planning CME/CE activities in a manner that may affect content:, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; Jan Shultz, RN, MSN, CCMEP and Patricia Staples, MSN, NP-C, CCRN hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME/CE activity of any amount during the past 12 months.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Postgraduate Institute for Medicine (PIM), ViralEd, Inc. and Merck & Co. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Postgraduate Institute for Medicine, ViralEd, Inc. and Merck & Co. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
There are no fees for participating and receiving credit for this activity. During the period, May 1, 2012 through May 1, 2013 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and evaluation form.
To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on the Submit Post-test at the bottom of the page. Your post-test will automatically be graded.
If you successfully complete the post-test (score of 70% or higher). your certificate will be made available immediately. Click on View Certificate and print the certificate for your records. If you received a score of 69% or less, you will receive a message notifying you that you did not pass the post-test. You may retake the post-test until successful.
You may complete the post-test online at: www.cmeuniversity.com
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Supported by an educational grant from Merck & Co., Inc.
This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings
